Here we provide a selection of scientific publications related to IOZK immunotherapy. You can use the filters to make a selection according to tumor types and methods, or enter search terms.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-8https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-82008-12-06 00:00:002008-12-06 00:00:00Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-12-04 / Lung Cancer 2009 Jul;65(1):1-8https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-12-04 / Lung Cancer 2009 Jul;65(1):1-82008-12-04 00:00:002019-02-15 08:34:57Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-12-01 / Int J Hyperthermia 2008 Dec;24(8):649-62https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-12-01 / Int J Hyperthermia 2008 Dec;24(8):649-622008-12-01 00:00:002019-02-15 09:17:39Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-28 / Cancer Lett. 2008 Nov;271(2):333-41https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-28 / Cancer Lett. 2008 Nov;271(2):333-412008-11-28 00:00:002019-02-15 09:16:51Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-41https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-412008-11-27 00:00:002019-02-15 09:19:13Dendritic cells in the skin–potential use for melanoma treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-80https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-802008-11-16 00:00:002019-02-15 08:44:32Recent advances in cancer vaccines: an overview
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-15 / Cancer Res. 2008 Nov;68(22):9441-50https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-502008-11-15 00:00:002019-02-15 09:19:16Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-9002008-11-08 00:00:002021-11-15 17:03:25Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-8https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-82008-11-01 00:00:002019-02-15 09:19:15[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-403https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-4032008-10-23 00:00:002019-02-15 09:19:13The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-32https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-322008-10-01 00:00:002021-11-15 17:03:44Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study
Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol
Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
Dendritic cells in the skin–potential use for melanoma treatment
Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
Recent advances in cancer vaccines: an overview
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients
[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
Dendritic cell vaccines for the treatment of prostate cancer
Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo
The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model
The anti-tumor effect of human monocyte-derived dendritic cells loaded with HSV-TK/GCV induced dying cells
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2